InvestorsObserver
×
News Home

Do Traders Think Unicycive Therapeutics Inc (UNCY) Can Turn Around Thursday?

Thursday, March 23, 2023 12:27 PM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Unicycive Therapeutics Inc (UNCY) Can Turn Around Thursday?

Unicycive Therapeutics Inc (UNCY) stock is lower by 10.19% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Unicycive Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on UNCY!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With UNCY Stock Today?

Unicycive Therapeutics Inc (UNCY) stock is lower by -11.76% while the S&P 500 has risen 1.37% as of 12:25 PM on Thursday, Mar 23. UNCY is down -$0.26 from the previous closing price of $2.20 on volume of 573,205 shares. Over the past year the S&P 500 is lower by -11.54% while UNCY has risen 48.09%. UNCY lost -$1.03 per share in the over the last 12 months.

More About Unicycive Therapeutics Inc

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Click Here to get the full Stock Report for Unicycive Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App